Lung Cancer Clinical Trial
Skeletal Muscle Atrophy and Dysfunction in Human Cancer
Summary
Cancer and its treatment can have profound effects on skeletal muscle, the most well-recognized being atrophy, weakness and diminished oxidative capacity. These adaptations negatively impact quality of life, treatment decisions and survival. Despite these consequences, the factors promoting these adaptations remain poorly defined and understudied in human patients. To address this gap in knowledge, our goal in this study is to examine the role of muscle disuse as a regulator of muscle size and function in human cancer patients
Eligibility Criteria
Inclusion Criteria:
50-75 yrs of age
histologically-documented, stage III or IV non-small cell lung carcinoma (NSCLC)
estimated life expectancy >6 mos
Karnofsky's performance score of ≥70
Exclusion Criteria:
history, signs or symptoms of inflammatory or autoimmune disease
uncontrolled hypertension
heart or renal failure
exercise limitations from peripheral vascular disease or stroke
neuromuscular disease
knee/hip replacement
additional, actively-treated malignancy or history of malignancy, except non-melanoma skin cancer
taking medication that can have anti-coagulant effects that cannot be stopped prior to the muscle biopsy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?